JP4838514B2 - 低粘度液体剤形 - Google Patents

低粘度液体剤形 Download PDF

Info

Publication number
JP4838514B2
JP4838514B2 JP2004570751A JP2004570751A JP4838514B2 JP 4838514 B2 JP4838514 B2 JP 4838514B2 JP 2004570751 A JP2004570751 A JP 2004570751A JP 2004570751 A JP2004570751 A JP 2004570751A JP 4838514 B2 JP4838514 B2 JP 4838514B2
Authority
JP
Japan
Prior art keywords
chloride
dosage form
active substance
bromide
liquid dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004570751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510726A (ja
JP2006510726A5 (enExample
Inventor
トゥーラ ライド
ニルス ライド
ウイリアム エイチ． ボッシュ
ジョン ディー． プルート
クリスチャン エフ． ワルツ
Original Assignee
エラン ファーマ インターナショナル，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32474388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4838514(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エラン ファーマ インターナショナル，リミティド filed Critical エラン ファーマ インターナショナル，リミティド
Publication of JP2006510726A publication Critical patent/JP2006510726A/ja
Publication of JP2006510726A5 publication Critical patent/JP2006510726A5/ja
Application granted granted Critical
Publication of JP4838514B2 publication Critical patent/JP4838514B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
JP2004570751A 2002-12-03 2003-04-23 低粘度液体剤形 Expired - Fee Related JP4838514B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43034802P 2002-12-03 2002-12-03
US60/430,348 2002-12-03
US10/412,669 2003-04-14
US10/412,669 US7101576B2 (en) 2002-04-12 2003-04-14 Nanoparticulate megestrol formulations
PCT/US2003/012660 WO2004050059A1 (en) 2002-12-03 2003-04-23 Low viscosity liquid dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011160522A Division JP2011251989A (ja) 2002-12-03 2011-07-22 低粘度液体剤形

Publications (3)

Publication Number Publication Date
JP2006510726A JP2006510726A (ja) 2006-03-30
JP2006510726A5 JP2006510726A5 (enExample) 2010-09-16
JP4838514B2 true JP4838514B2 (ja) 2011-12-14

Family

ID=32474388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004570751A Expired - Fee Related JP4838514B2 (ja) 2002-12-03 2003-04-23 低粘度液体剤形
JP2011160522A Pending JP2011251989A (ja) 2002-12-03 2011-07-22 低粘度液体剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011160522A Pending JP2011251989A (ja) 2002-12-03 2011-07-22 低粘度液体剤形

Country Status (6)

Country Link
US (1) US7101576B2 (enExample)
EP (2) EP1613276A1 (enExample)
JP (2) JP4838514B2 (enExample)
AU (1) AU2003231071A1 (enExample)
CA (1) CA2508301A1 (enExample)
WO (1) WO2004050059A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
JP4865990B2 (ja) * 2002-04-12 2012-02-01 エラン ファーマ インターナショナル，リミティド ナノ粒子メゲストロール製剤
ES2342935T3 (es) * 2003-01-13 2010-07-19 THE PROCTER & GAMBLE COMPANY Composiciones para prevencion y tratamiento de sintomas de tipo resfriado y gripe que comprenden polimeros mucoadhesivos seleccionados.
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
ATE469650T1 (de) 2004-12-01 2010-06-15 Par Pharmaceuticals Inc Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz
WO2006066063A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
DK2727583T3 (da) 2004-12-22 2021-12-20 Nitto Denko Corp Lægemiddelbærer og lægemiddelbærerkit til at inhibere fibrose
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP2008526855A (ja) * 2005-01-06 2008-07-24 エラン ファーマ インターナショナル リミテッド ナノ粒子のカンデサルタン製剤
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
WO2006110811A1 (en) 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
AU2006309295B2 (en) * 2005-06-03 2012-04-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
WO2006135635A2 (en) 2005-06-10 2006-12-21 Scott Donald E Topical compositions and methods for alleviating or inhibiting symptoms associated with carpal tunnel syndrome, acid reflux, psoriasis, cartilage nodules, fibromyalgia, and diabetes
WO2007002315A2 (en) * 2005-06-22 2007-01-04 Elan Pharma International, Limited Nanoparticulate megestrol formulations
PL1749531T3 (pl) * 2005-08-03 2016-01-29 Par Pharmaceuticals Inc Zastosowanie doustnej zawiesiny zawierającej octan megestrolu do leczenia astmy oskrzelowej
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP2009526087A (ja) * 2005-12-22 2009-07-16 アナボレックス， インコーポレイテッド 悪液質の予防および処置のための組成物および方法
US20070196498A1 (en) * 2006-02-22 2007-08-23 Sherman Bernard C Megestrol acetate suspension
SG173315A1 (en) * 2006-06-23 2011-08-29 Tibotec Pharm Ltd Aqueous suspensions of tmc278
EP2054042B8 (en) 2006-06-30 2020-06-10 iCeutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
WO2008027571A2 (en) * 2006-08-30 2008-03-06 Liquidia Technologies, Inc. Nanoparticles having functional additives for self and directed assembly and methods of fabricating same
WO2008066899A2 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
DE102006057904A1 (de) * 2006-12-08 2008-06-12 Dow Wolff Cellulosics Gmbh Herstellung von Cellulose-Nanopartikeln
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
WO2008129308A2 (en) * 2007-04-24 2008-10-30 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
US8003621B2 (en) 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
WO2009038533A1 (en) * 2007-09-17 2009-03-26 Bioneris Ab Method and means for the treatment of cachexia
EP2200588B1 (en) * 2007-09-25 2019-03-20 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
WO2009056256A1 (en) * 2007-11-02 2009-05-07 Par Pharmaceuticals, Inc. Use of megestrol acetate having improved solubility for the treatment of cancer cachexia
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR100958138B1 (ko) * 2008-01-10 2010-05-18 박성순 안정성이 우수한 초산메게스트롤 약학 조성물 및 그제조방법
US20100055246A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nutrition delivery capsules for functional foods
US20100055187A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nanovitamin synthesis
KR20170075024A (ko) 2009-04-24 2017-06-30 아이슈티카 피티와이 리미티드 신규 멜록시캄 제제
MX351930B (es) 2009-04-24 2017-11-03 Iceutica Pty Ltd Una formulacion novedosa de indometacina.
MA33295B1 (fr) 2009-04-24 2012-05-02 Iceutica Pty Ltd Nouvelle formulation de diclofénac
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
JP5910084B2 (ja) * 2009-12-18 2016-04-27 株式会社カネカ 液状食品組成物
JP5636211B2 (ja) * 2010-05-31 2014-12-03 株式会社 日立産業制御ソリューションズ 異物検査装置および異物検査方法
SG10201802116RA (en) 2010-08-18 2018-04-27 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
EP2726066B1 (en) 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosage forms of amphetamine for oral administration
EP2758043A4 (en) 2011-08-17 2016-02-24 Dennis M Brown COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL
WO2013074526A2 (en) 2011-11-15 2013-05-23 Byocoat Enterprises, Inc. Antimicrobial compositions and methods of use thereof
JP2015501802A (ja) 2011-11-17 2015-01-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 眼への薬物送達を向上させるための方法および組成物、ならびに徐放性送達製剤
US10201521B2 (en) 2012-01-20 2019-02-12 Del Mar Pharmaceuticals (Bc) Ltd. Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem and cancer stem cells including glioblastoma multiforme and medulloblastoma
WO2013133903A1 (en) * 2012-03-05 2013-09-12 Aerodesigns, Inc. Particles for aerosolizing apparatus
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
KR102373259B1 (ko) * 2012-05-03 2022-03-17 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
WO2013169600A1 (en) 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
JP6666840B2 (ja) * 2013-08-01 2020-03-18 エムダブリュ エンキャップ リミテッド 低水溶性薬剤の低融解イオン性塩の組成物および調製方法
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
CN115316401A (zh) * 2022-07-27 2022-11-11 黑龙江实创农业技术开发有限责任公司 一种应用于植株促生长的粒子能量制剂及制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH06199658A (ja) * 1992-12-15 1994-07-19 Sterling Winthrop Inc ナノ粒子を含む組成物及びその製造方法
JPH07165562A (ja) * 1992-07-01 1995-06-27 Sterling Winthrop Inc 表面を修飾された抗癌性ナノ粒子
WO1997010814A1 (en) * 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
WO2001012229A1 (en) * 1999-08-17 2001-02-22 Ivax-Cr A.S. Pharmaceutical compositions for oral and topical administration
JP2001316274A (ja) * 2000-05-08 2001-11-13 Asahi Kasei Corp 経管栄養剤およびその製造方法
WO2001091750A1 (en) * 2000-05-26 2001-12-06 Pharmacia Corporation Use of a celecoxib composition for fast pain relief
WO2001097779A2 (en) * 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
JP2002540080A (ja) * 1999-03-19 2002-11-26 パーカー ヒューズ インスティテュート ゲルミクロ乳濁液製剤

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
HUT50044A (en) * 1988-04-12 1989-12-28 Bristol Myers Co Process for producing pharmaceutical composition comprising megestrol acetate as active ingredient
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5338732A (en) 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
AU2317592A (en) 1991-07-05 1993-02-11 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
ES2148345T3 (es) 1993-10-22 2000-10-16 Hexal Ag Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
GB9718568D0 (en) 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
US6268356B1 (en) 1998-04-20 2001-07-31 Pharmaceutical Resources, Inc. Flocculated suspension of megestrol acetate
US6028065A (en) 1998-04-20 2000-02-22 Pharmaceutical Resources, Inc. Flocculated suspension of megestrol acetate
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2000072973A1 (en) 1999-06-01 2000-12-07 Elan Pharma International Ltd. Small-scale mill and method thereof
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6656505B2 (en) 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20020028794A1 (en) 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
DE60137362D1 (de) * 2000-11-20 2009-02-26 Elan Pharma Int Ltd Nanopartikel bestehend aus einem arzneistoff und copolymeren von vinyl pyrrolidon und vinyl acetat als oberflächenstabilisatoren
DE60227802D1 (de) 2001-06-05 2008-09-04 Elan Pharma Int Ltd Mahlvorrichtung und verfahren zu deren betrieb
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04295420A (ja) * 1991-01-25 1992-10-20 Sterling Winthrop Inc 表面変性薬物微小粒子
JPH07165562A (ja) * 1992-07-01 1995-06-27 Sterling Winthrop Inc 表面を修飾された抗癌性ナノ粒子
JPH06199658A (ja) * 1992-12-15 1994-07-19 Sterling Winthrop Inc ナノ粒子を含む組成物及びその製造方法
WO1997010814A1 (en) * 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
JP2002540080A (ja) * 1999-03-19 2002-11-26 パーカー ヒューズ インスティテュート ゲルミクロ乳濁液製剤
WO2001012229A1 (en) * 1999-08-17 2001-02-22 Ivax-Cr A.S. Pharmaceutical compositions for oral and topical administration
JP2001316274A (ja) * 2000-05-08 2001-11-13 Asahi Kasei Corp 経管栄養剤およびその製造方法
WO2001091750A1 (en) * 2000-05-26 2001-12-06 Pharmacia Corporation Use of a celecoxib composition for fast pain relief
WO2001097779A2 (en) * 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol

Also Published As

Publication number Publication date
CA2508301A1 (en) 2004-06-17
JP2011251989A (ja) 2011-12-15
WO2004050059A1 (en) 2004-06-17
JP2006510726A (ja) 2006-03-30
AU2003231071A1 (en) 2004-06-23
EP2263651A2 (en) 2010-12-22
US20030219490A1 (en) 2003-11-27
EP1613276A1 (en) 2006-01-11
EP2263651A3 (en) 2011-09-14
US7101576B2 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
JP4838514B2 (ja) 低粘度液体剤形
US20040105889A1 (en) Low viscosity liquid dosage forms
US9101549B2 (en) Nanoparticulate megestrol formulations
JP4776229B2 (ja) 安定なナノ粒子活性物質の液体投与組成物
JP4611641B2 (ja) Ｍａｐキナーゼ阻害剤のナノ粒子組成物
US20050004049A1 (en) Novel griseofulvin compositions
JP2005529911A (ja) ナノ粒子ナイスタチン製剤
JP2010248220A (ja) ナノ粒子メゲストロール製剤
EP1658053A2 (en) Novel compositions of sildenafil free base
JP2009508859A (ja) ナノ粒子アリピプラゾール製剤
KR20080017065A (ko) 나노입자형 아세트아미노펜 제제
US20120087955A1 (en) Nanoparticulate megestrol formulations
JP2008546796A (ja) ナノ微粒子メゲストロール製剤
EP1935407A1 (en) Low viscosity liquid dosage forms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100326

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110811

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110907

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110930

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141007

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees